Clinical trials
PD-1 Inhibitor clinical trials
Below are recruiting pd-1 inhibitor clinical trials, each written for real people, not researchers. We’re tracking 198 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06802757RecruitingPhase 2
Study of posaconazole with immunotherapy and chemo for triple-negative breast cancer
This trial tests if adding posaconazole (an antifungal drug) to standard immunotherapy and chemotherapy before breast cancer surgery works better than just the standard treatment. It is for people with newly diagnosed, early-stage triple-negative breast cancer.
Jinan, ShandongAges 18–70 - NCT06802835RecruitingPhase 1/Phase 2
EGFR antibody plus immunotherapy and chemo for advanced nasopharyngeal cancer
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–75 - NCT06958432RecruitingPhase 2/Phase 3
Short-course radiation plus chemo and immunotherapy for rectal cancer
This trial tests a treatment plan that uses a short course of radiation to the lymph nodes-sparing area, followed by chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of mid or low rectal cancer (pMMR/MSS). The goal is to see if this approach can shrink the tumor and improve outcomes without needing extensive surgery.
Guangzhou, GuangdongAges 18–75 - NCT06964568RecruitingPhase 3
Chemoradiation followed by immunotherapy for esophageal cancer
This trial tests a treatment for locally advanced esophageal cancer. You'll receive chemoradiation (chemo plus radiation) followed by a maintenance drug (a PD-1 inhibitor) to help prevent the cancer from coming back.
ShanghaiAges 18 years+ - NCT07034391RecruitingPhase 2
PD-1 inhibitor with denosumab and chemo for advanced lung cancer
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor), a bone-strengthening drug (denosumab), and chemotherapy for people with advanced or spread non-squamous non-small cell lung cancer that does not have certain genetic changes. The goal is to see if this combination helps shrink tumors and control the disease.
Shenyang, LiaoningAges 18–75 - NCT07070479RecruitingPhase 2
Combination treatment for PD-1 resistant nasopharyngeal cancer
This trial is testing a combination of drugs for people whose nasopharyngeal cancer has stopped responding to standard treatments like platinum chemotherapy and PD-1 inhibitors. It aims to find a new effective approach for advanced or recurrent disease.
Guangzhou, GuangdongAges 18–70 - NCT07086300Recruiting
Acupuncture with immunotherapy for older lung cancer patients
This trial tests whether adding electroacupuncture (a gentle, needle-based therapy) to a standard immunotherapy drug (PD-1 inhibitor) can help older adults with advanced lung cancer. It may improve treatment response and quality of life.
Tianjin, Tianjin MunicipalityAges 65–100 - NCT07125547RecruitingPhase 2
Immunotherapy and chemo before surgery for ureteral cancer
This trial tests a combination of immunotherapy (tislelizumab) and chemotherapy (nab-paclitaxel) given before surgery for ureteral cancer. The goal is to see if the treatment shrinks the tumor and makes the surgery more effective.
Tianjin, Outside U.S.Ages 18 years+ - NCT07198165RecruitingPhase 2
Short radiation followed by chemo plus bevacizumab with or without immunotherapy for rectal cancer
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemoradiation and targeted therapy improves outcomes for locally advanced rectal cancer. It is for patients who have not had prior treatment and do not have certain genetic markers (BRAF mutation or MSI-H).
ShanghaiAges 18–75 - NCT07239661Recruiting
Acupuncture plus immunotherapy for advanced lung cancer
This trial tests whether adding electroacupuncture to a PD-1 inhibitor (a type of immunotherapy) can help people with advanced non-small cell lung cancer who have limited activity levels. It may improve treatment response and quality of life.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07272382Recruiting
Omega-3 supplements with immunotherapy for advanced esophageal cancer
This trial tests whether adding omega-3 fatty acid supplements to a PD-1 inhibitor (a type of immunotherapy) can help control advanced esophageal cancer. It is for people whose cancer has spread or returned, and who have not already failed a similar immunotherapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07279077RecruitingPhase 2
Low-dose radiation with chemo and immunotherapy for high-risk colon cancer
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of high-risk colon cancer that has not spread. The goal is to see if this approach can shrink the tumor before surgery and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07312422RecruitingPhase 1/Phase 2
Low-dose radiation with immunotherapy and standard therapy for advanced pancreatic cancer
This trial combines low-dose radiation with an immunotherapy drug (pucotenlimab) and standard treatment for advanced pancreatic cancer. It aims to see if this triple therapy can help control the cancer without using a PD-1/PD-L1 inhibitor before.
Hangzhou, ZhejiangAges 18–75 - NCT07359040Recruiting
Testing a new drug before surgery for lung cancer
This trial studies whether a new drug called Ivonescimab can improve outcomes when given before surgery for non-small cell lung cancer. It may help shrink tumors and make them easier to remove.
Beijing, Beijing MunicipalityAges Any age - NCT02821013RecruitingPhase 3
Testing how long to take PD-1 therapy for melanoma
This trial studies whether people with metastatic melanoma should take PD-1 immunotherapy continuously or only for a limited time. It aims to find a schedule that keeps the cancer under control while possibly reducing treatment burden.
Victoria, MilduraAges 18 years+ - NCT07404332RecruitingPhase 1
Combination therapy for tumors resistant to immunotherapy
This trial tests a combination of two drugs (5-Azacitidine and a PD-1/PD-L1 inhibitor) for people whose solid tumors stopped responding to standard PD-1/PD-L1 immunotherapy alone. The goal is to see if this new combination can help shrink the tumor or slow its growth.
Iowa City, IowaAges 18–99 - NCT07458529RecruitingPhase 2
Chemoradiation plus immunotherapy with or without probiotics for rectal cancer
This trial tests adding an immunotherapy drug (tislelizumab) and a probiotic to standard chemoradiation for locally advanced rectal cancer that has not spread. The goal is to see if the probiotic helps the treatment work better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07472153RecruitingPhase 2/Phase 3
Immunotherapy plus chemo for advanced cervical cancer
This trial tests adding immunotherapy drugs (PD-1 or PD-L1 inhibitors) to standard chemotherapy, with or without bevacizumab, for people with cervical cancer that has spread, persisted, or come back after treatment. The goal is to see which combination works better.
Minsk, LesnoyAges 18–75 - NCT07489989RecruitingPhase 2
Combination therapy to boost CAR-T for B-cell lymphoma
This trial tests a new combination of drugs to make CAR-T cell therapy work better for people with certain types of B-cell lymphoma. It adds the drugs chidamide and a PD-1 inhibitor to the usual CAR-T treatment, aiming to improve response.
Beijing, Beijing MunicipalityAges 18–85 - NCT07504471RecruitingPhase 2
Bicarbonate plus chemo and immunotherapy for pancreatic cancer liver spread
This trial tests adding sodium bicarbonate to a chemotherapy plus immunotherapy regimen for pancreatic cancer that has spread to the liver. The goal is to see if this combination helps shrink tumors and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07644286RecruitingPhase 2
Pirfenidone and immunotherapy with optional radiation for advanced colorectal cancer
This study tests a combination of three treatments—pirfenidone (an anti-scarring drug), a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), and sometimes radiation—for colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can slow or shrink your cancer.
Wuhan, HubeiAges 18–75 - NCT06301399RecruitingPhase 2
Rituximab with prior therapy for advanced liver cancer
This trial tests if adding rituximab to previous cancer treatments can help people with advanced hepatocellular carcinoma (a type of liver cancer) that has stopped responding or caused side effects. It aims to see if this combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 17–79 - NCT06702566Recruiting
Study of Ferritin in Immune-Related Side Effects
This study looks at how a blood marker called ferritin relates to side effects from immunotherapy or other cancer treatments. It may help doctors predict and manage those side effects better.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07068763RecruitingPhase 2
Short radiation plus drugs for early rectal cancer
This trial tests a combination of short-course radiation, chemotherapy (capecitabine), and two immunotherapy drugs (PD-1 and CTLA-4 inhibitors) for people with early-stage rectal cancer who want to avoid surgery and keep their anus. The goal is to see if this treatment can shrink the tumor enough to avoid major surgery.
Hangzhou, ZhejiangAges 18–80
Hear when a new PD-1 Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pd-1 inhibitor?
- Yes. Clin2 currently lists 198 recruiting pd-1 inhibitor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pd-1 inhibitor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pd-1 inhibitor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.